Serum peptidomic profiling identifies a minimal residual disease detection and prognostic biomarker for patients with acute leukemia

Song,Wei; Wang,Na; Li,Wei; Wang,Guanjun; Hu,Jifan; He,Kun; Li,Yan; Meng,Ying; Chen,Naifei; Wang,Shaoxin; Hu,Lingyun; Xu,Bin; Wang,Jie; Li,Ailing; Cui,Jiuwei

doi:10.3892/ol.2013.1574

Serum peptidomic profiling identifies a minimal residual disease detection and prognostic biomarker for patients with acute leukemia

Authors:
- Wei Song
- Na Wang
- Wei Li
- Guanjun Wang
- Jifan Hu
- Kun He
- Yan Li
- Ying Meng
- Naifei Chen
- Shaoxin Wang
- Lingyun Hu
- Bin Xu
- Jie Wang
- Ailing Li
- Jiuwei Cui
View Affiliations

Affiliations: Cancer Center, The First Hospital of Jilin University, Changchun, Jilin, P.R. China, Institute of Basic Medical Sciences, National Center of Biomedical Analysis, Beijing, P.R. China
Published online on: September 12, 2013 https://doi.org/10.3892/ol.2013.1574
Pages: 1453-1460

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The evaluation of minimal residual disease (MRD) in acute leukemia (AL) is currently recognized as a potential critical tool to assess the response and relapse rate of treatments. The present study investigated serum peptides from patients with AL to identify biomarkers that would be useful in providing clinical evaluations and independent prognostic information. The patterns of serum peptides from 123 patients with AL and 49 healthy controls were analyzed using matrix‑assisted laser desorption/ionization‑time of flight mass spectrometry. Furthermore, diagnostic models of differential peptides were established using the support vector machine (SVM) algorithm to discriminate between the AL patients and healthy controls or between the AL patients with various degrees of remission. Finally, the peptides were applied to evaluate the prognosis of the affected patients. The area under the receiver operating characteristic (ROC) curve (AUC), analyzed using the SVM algorithm to distinguish between the AL patients and healthy controls, was 0.921. The AUC of the models for distinguishing between the newly‑diagnosed AL patients and those in AL‑hematological complete remission (HCR) and between the AL‑HCR patients from those in AL‑molecular remission (MR), was 0.824 and 0.919, respectively. A short serum peptide of m/z 4625 was identified to decrease in density in parallel with an increase in the degree of remission, which was used to monitor the MRD level. The intensity of the m/z 4625 peptide was significantly correlated with a poor overall survival (OS). The m/z 4625 peptide was identified to be a partial fragment of SERPINA3. The serum peptide pattern is high in sensitivity and specificity and may be used to discriminate between AL patients with various degrees of remission. The m/z 4625 peptide may be used to monitor the MRD levels and provide independent prognostic information in patients with AL.

View Figures

View References

1	Falini B, Tiacci E, Martelli MP, Ascani S and Pileri SA: Acute myeloid leukemia (AML) and related precursor neoplasms. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al: 4th edition. IARC; Lyon, France: pp. 109–147. 2008
2	Pui CH, Relling MV and Downing JR: Acute lymphoblastic leukemia. N Engl J Med. 350:1535–1548. 2004. View Article : Google Scholar : PubMed/NCBI
3	Kantarjian HM, O’Brien S, Smith TL, Cortes J, Giles FJ, Beran M, et al: Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol. 18:547–561. 2000.PubMed/NCBI
4	Annino L, Vegna ML, Camera A, Specchia G, Visani G, Fioritoni G, et al: Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood. 99:863–871. 2002. View Article : Google Scholar : PubMed/NCBI
5	Cassileth PA, Harrington DP, Appelbaum FR, Lazarus HM, Rowe JM, Paietta E, et al: Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management to acute myeloid leukemia in first remission. N Engl J Med. 339:1649–1656. 1998. View Article : Google Scholar : PubMed/NCBI
6	Dworzak MN, Fröschl G, Printz D, Mann G, Pötschger U, Mühlegger N, et al; Austrian Berlin-Frankfurt-Münster Study Group. Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. Blood. 99:1952–1958. 2002. View Article : Google Scholar : PubMed/NCBI
7	Mortuza FY, Papaioannou M, Moreira IM, Coyle LA, Gameiro P, Gandini D, et al: Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia. J Clin Oncol. 20:1094–1104. 2002. View Article : Google Scholar : PubMed/NCBI
8	Campana D: Determination of minimal residual disease in leukemia patients. Br J Haematol. 121:823–838. 2003. View Article : Google Scholar : PubMed/NCBI
9	San Miguel JF, Vidriales MB, López-Berges C, Díaz-Mediavilla J, Gutiérrez N, Cañizo C, et al: Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood. 98:1746–1751. 2001.
10	Guerrasio A, Pilatrino C, De Micheli D, Cilloni D, Serra A, Gottardi E, et al: Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcripts. Leukemia. 16:1176–1181. 2002. View Article : Google Scholar : PubMed/NCBI
11	van Dongen JJ, Seriu T, Panzer-Grümayer ER, Biondi A, Pongers-Willemse MJ, Corral L, et al: Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet. 352:1731–1738. 1998.
12	Schmidt HH, Strehl S, Thaler D, Strunk D, Sill H, Linkesch W, et al: RT-PCR and FISH analysis of acute myeloid leukemia with t(8;21)(p11;p13) and chimeric MOZ and CBP transcripts: breakpoint cluster region and clinical implications. Leukemia. 18:1115–1121. 2004. View Article : Google Scholar
13	Fiedler GM, Leichtle AB, Kase J, Baumann S, Ceglarek U, Felix K, Conrad T, Witzigmann H, Weimann A, Schütte C, Hauss J, Büchler M and Thiery J: Serum peptidome profiling revealed platelet factor 4 as a potential discriminating Peptide associated with pancreatic cancer. Clin Cancer Res. 15:3812–3819. 2009. View Article : Google Scholar
14	Patz EF Jr, Campa MJ, Gottlin EB, Kusmartseva I, Guan XR and Herndon JE 2nd: Panel of serum biomarkers for the diagnosis of lung cancer. J Clin Oncol. 25:5578–5583. 2007. View Article : Google Scholar : PubMed/NCBI
15	Visintin I, Feng Z, Longton G, Ward DC, Alvero AB, Lai Y, et al: Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res. 14:1065–1072. 2008. View Article : Google Scholar : PubMed/NCBI
16	Kornblau SM, Tibes R, Qiu YH, Chen W, Kantarjian HM, Andreeff M, et al: Functional proteomic profiling of AML predicts response and survival. Blood. 113:154–164. 2009. View Article : Google Scholar : PubMed/NCBI
17	Cui JW, Li WH, Wang J, Li AL, Li HY, Wang HX, et al: Proteomics-based identification of human acute leukemia antigens that induce humoral immune response. Mol Cell Proteomics. 4:1718–1724. 2005. View Article : Google Scholar : PubMed/NCBI
18	Liang T, Wang N, Li W, Li A, Wang J, Cui J, et al: Identification of complement C3f-desArg and its derivative for acute leukemia diagnosis and minimal residual disease assessment. Proteomics. 10:90–98. 2010. View Article : Google Scholar : PubMed/NCBI
19	Cao Y, Wang N, Ying X, Li A, Wang H, Zhang X and Li W: BioSunMS: a plug-in-based software for the management of patients information and the analysis of peptide profiles from mass spectrometry. BMC Med Inform Decis Mak. 9:132009. View Article : Google Scholar : PubMed/NCBI
20	Ng KL and Mishra SK: De novo SVM classification of precursor microRNAs from genomic pseudo hairpins using global and intrinsic folding measures. Bioinformatics. 23:1321–1330. 2007. View Article : Google Scholar : PubMed/NCBI
21	Licastro F, Pedrini S, Ferri C, Casadei V, Govoni M, Pession A, et al: Gene polymorphism affecting alpha1-antichymotrypsin and interleukin-1 plasma levels increases Alzheimer’s disease risk. Ann Neurol. 48:388–391. 2000.PubMed/NCBI
22	Bird PI: Regulation of pro-apoptotic leucocyte granule serine proteinases by intracellular serpins. Immunol Cell Biol. 77:47–57. 1999. View Article : Google Scholar : PubMed/NCBI
23	Kloth JN, Gorter A, Fleuren GJ, Oosting J, Uljee S, ter Haar N, et al: Elevated expression of SerpinA1 and SerpinA3 in HLA-positive cervical carcinoma. J Pathol. 215:222–230. 2008. View Article : Google Scholar : PubMed/NCBI
24	Lai ML, Rizzo N, Liguori C, Zucca G and Faa G: Alpha-1-antichymotrypsin immunoreactivity in papillary carcinoma of the thyroid gland. Histopathology. 33:332–336. 1998. View Article : Google Scholar : PubMed/NCBI
25	Estellés A, Gilabert J, Grancha S, Yamamoto K, Thinnes T, España F, et al: Abnormal expression of type 1 plasminogen activator inhibitor and tissue factor in severe preeclampsia. Thromb Haemost. 79:500–508. 1998.PubMed/NCBI
26	Wang Y, Jiang H, Dai D, Su M, Martinka M, Brasher P, et al: Alpha 1 antichymotrypsin is aberrantly expressed during melanoma progression and predicts poor survival for patients with metastatic melanoma. Pigment Cell Melanoma Res. 23:575–578. 2010. View Article : Google Scholar : PubMed/NCBI